SCHEMBL193433

SCHEMBL193433

CC(O)NP(=O)(O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16177833 0.81 MMP1 (0.36)
SCHEMBL3486881 0.78
Hydrochloric Acid SCHEMBL28132101 0.75
SCHEMBL8633128 0.75 CA2 (0.33)
SCHEMBL42677 0.75 TP53 (0.38)
SCHEMBL42674 0.75 TP53 (0.38)
SCHEMBL72230 0.75 ACE (0.48)
SCHEMBL72229 0.75 ACE (0.48)
SCHEMBL9392111 0.73
SCHEMBL9395461 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
CN-105755485-A Novel water soluble metal pickling corrosion inhibitor and application thereof 四川理工学院 2016-07-13 CN claimed
US-20100292294-A1 Compositions Comprising a Physiological Coolant GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2010-11-18 US claimed
EP-2134319-A2 COMPOSITIONS COMPRISING A PHYSIOLOGICAL COOLANT Givaudan Nederland Services B.V. (NL) 2009-12-23 EP claimed
WO-2008107137-A2 COMPOSITIONS COMPRISING A PHYSIOLOGICAL COOLANT GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-09-12 WO claimed
EP-1361872-A4 NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS UNIV VIRGINIA (US) 2004-05-19 EP claimed
EP-1361872-A2 NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2003-11-19 EP claimed
WO-2002029001-A2 NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS UNIVERSITY OF VIRGINIAN PATENT FOUNDATION (US) 2002-04-11 WO claimed
EP-0730860-B1 Mixed micelles HOFFMANN LA ROCHE (CH) 2002-01-02 EP claimed
EP-0730860-A2 Mixed micelles F. HOFFMANN-LA ROCHE AG (CH) 1996-09-11 EP claimed
US-20240010984-A1 SERUM-FREE MEDIUM FOR DIFFERENTIATION OF A PROGENITOR CELL Mosa Meat B.V. (NL) 2024-01-11 US disclosed
EP-4251740-A1 SERUM-FREE MEDIUM FOR DIFFERENTIATION OF A PROGENITOR CELL Mosa Meat B.V. (NL) 2023-10-04 EP disclosed
CN-116685676-A Serum-free medium for progenitor cell differentiation 莫萨米特有限公司 2023-09-01 CN disclosed
WO-2023003471-A1 METHOD FOR PRODUCING CULTURED FAT FOR ANIMAL CONSUMPTION. Mosa Meat B.V. (NL) 2023-01-26 WO disclosed
WO-2022114955-A1 SERUM-FREE MEDIUM FOR DIFFERENTIATION OF A PROGENITOR CELL Mosa Meat B.V. (NL) 2022-06-02 WO disclosed
US-20040147562-A1 Methods of treating conditions associated with an EDG-1 receptor MANIV ENERGY CAPITAL 2004-07-29 US disclosed
WO-2004053459-A2 COMPOUNDS AND MEHTODS OF USE THEREOF FOR ASSAYING LYSOPHOSPHOLIPASE D ACTIVITY ECHELON BIOSCIENCES INCORPORATED (US) 2004-06-24 WO disclosed
US-20040122236-A1 Novel lysophosphatidic acid receptor agonists and antagonists UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2004-06-24 US disclosed
WO-2004009816-A1 METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-1 RECEPTOR CERETEK LLC (US) 2004-01-29 WO disclosed
WO-2003062392-A2 METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR CERETEK LLC (US) 2003-07-31 WO disclosed